Asymmetric Organic Synthesis in Drug Design and Catalysis
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Cross-Field Chemistry".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 73
Special Issue Editor
Special Issue Information
Dear Colleagues,
Medicines are part of our everyday life. Active pharmaceutical ingredients are the top products of chemistry. Synthetic steps lacking optimization, expensive reagents, and chromatographic purifications are common during their discovery syntheses. Moreover, optical isomers are often separated using chiral chromatography. In the case of a chiral product, the common practice was to perform resolution at some point in the synthesis. The development of a resolution method requires special expertise (the choice of resolving agent, solvent, conditions, etc.). Either the undesired isomer is then incinerated, or a process is developed to recycle it. A greener and more economical way to create stereogenic centers is enantioselective catalysis. Chemists who develop a process rarely redesign a discovery synthesis, especially when the building blocks are readily available and inexpensive. Using enantioselective methods, the synthesis of biologically active substances can be carried out without any significant modification or resolution.
The tools of modern chemistry include homogeneous, heterogeneous, and phase transfer catalytic techniques that use chiral auxiliaries or reagents for the synthesis of optically active compounds. Moreover, flow systems are available to increase safety and efficiency of these techniques while maintaining their quality. These techniques can be used to develop asymmetric reactions that result in an active pharmaceutical ingredient or its intermediate. Whether a known reaction is transformed into an enantioselective one or a known compound is synthesized in a new way, a new tool will be put not only in the hands of the chemists performing the discovery synthesis but also in the hands of the process development chemists.
Articles are welcome on themes including, but not limited to, the following:
- The enantioselective catalytic synthesis of an active pharmaceutical ingredient (API);
- The enantioselective catalytic synthesis of (potential) pharmaceutical intermediates;
- The synthesis of (potential) pharmaceutical intermediates/APIs using chiral auxiliaries;
- The synthesis of (potential) pharmaceutical intermediates/APIs from a chiral pool;
- The improved synthetic method for a pharmaceutical intermediate/API;
- Continuous method for the synthesis of a pharmaceutical intermediate/API
Dr. Zsolt Rapi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- enantioselective synthesis
- chiral catalysis
- chiral auxiliaries
- active pharmaceutical ingredient
- pharmaceutical intermediate
